These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 23312567

  • 1. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial.
    Cutler AJ, Kalali AH, Mattingly GW, Kunovac J, Meng X.
    CNS Spectr; 2013 Feb; 18(1):43-54. PubMed ID: 23312567
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L, Meng X, Hochfeld M, Stahl SM.
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [Abstract] [Full Text] [Related]

  • 3. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
    Cutler AJ, Kalali AH, Weiden PJ, Hamilton J, Wolfgang CD.
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
    [Abstract] [Full Text] [Related]

  • 4. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
    Kane JM, Lauriello J, Laska E, Di Marino M, Wolfgang CD.
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
    [Abstract] [Full Text] [Related]

  • 5. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
    Weiden PJ, Cutler AJ, Polymeropoulos MH, Wolfgang CD.
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
    [Abstract] [Full Text] [Related]

  • 6. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic.
    Citrome L.
    Int J Clin Pract; 2009 Aug; 63(8):1237-48. PubMed ID: 19624791
    [Abstract] [Full Text] [Related]

  • 7. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G, Trixler M, Bitter I, Degrell I, Füredi J, Faludi G, Ziprasidonra Váltást Vizsgáló Munkacsoport.
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [Abstract] [Full Text] [Related]

  • 8. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.
    Depress Anxiety; 2007 Dec; 24(1):41-52. PubMed ID: 16845641
    [Abstract] [Full Text] [Related]

  • 9. Iloperidone for the treatment of schizophrenia.
    Marino J, Caballero J.
    Ann Pharmacother; 2010 May; 44(5):863-70. PubMed ID: 20388862
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Ratner Y, Gibel A, Yorkov V, Ritsner MS.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct 01; 31(7):1401-9. PubMed ID: 17669574
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies.
    Potkin SG, Litman RE, Torres R, Wolfgang CD.
    J Clin Psychopharmacol; 2008 Apr 01; 28(2 Suppl 1):S4-11. PubMed ID: 18334911
    [Abstract] [Full Text] [Related]

  • 12. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.
    Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D.
    J Psychopharmacol; 2011 May 01; 25(5):685-97. PubMed ID: 20615933
    [Abstract] [Full Text] [Related]

  • 13. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
    Tzimos A, Samokhvalov V, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M.
    Am J Geriatr Psychiatry; 2008 Jan 01; 16(1):31-43. PubMed ID: 18165460
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.
    Zhao T, Park TW, Yang JC, Huang GB, Kim MG, Lee KH, Chung YC.
    Int Clin Psychopharmacol; 2012 Jul 01; 27(4):184-90. PubMed ID: 22426471
    [Abstract] [Full Text] [Related]

  • 15. Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia.
    Citrome L, Weiden PJ, Alva G, Glick ID, Jackson R, Mattingly G, Kianifard F, Meng X, Winseck A.
    Clin Schizophr Relat Psychoses; 2015 Jan 01; 8(4):183-95. PubMed ID: 25367165
    [Abstract] [Full Text] [Related]

  • 16. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL, Burns T, Morosini P, Gagnon DD, Rothman M, Adriaenssen I.
    Clin Ther; 2010 Feb 01; 32(2):275-92. PubMed ID: 20206786
    [Abstract] [Full Text] [Related]

  • 17. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A, Ritsner MS.
    Clin Neuropharmacol; 2008 Feb 01; 31(4):204-20. PubMed ID: 18670244
    [Abstract] [Full Text] [Related]

  • 18. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H, Rui Q, Ning X, Xu H, Gu N.
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun 01; 35(4):1002-8. PubMed ID: 21315787
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis.
    Citrome L, Meng X, Hochfeld M.
    Schizophr Res; 2011 Sep 01; 131(1-3):75-81. PubMed ID: 21700430
    [Abstract] [Full Text] [Related]

  • 20. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.
    Durgam S, Starace A, Li D, Migliore R, Ruth A, Németh G, Laszlovszky I.
    Schizophr Res; 2014 Feb 01; 152(2-3):450-7. PubMed ID: 24412468
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.